Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Hudecek

Showing results (51-60 of 139) with videos related to

Pageof 14
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 27, 2013
Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cellsMichael Hudecek, Maria-Teresa Lupo-Stanghellini, Paula L Kosasih, et al.
Journal for Immunotherapy of Cancer|April 29, 2025
Tailoring CAR surface density and dynamics to improve CAR-T cell therapyAna Hinckley-Boned, Carmen Barbero-Jiménez, Maria Tristán-Manzano, et al.
Cancer Immunology Research|September 13, 2014
The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activityMichael Hudecek, Daniel Sommermeyer, Paula L Kosasih, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|January 20, 2017
Minicircle-Based Engineering of Chimeric Antigen Receptor (CAR) T CellsMichael Hudecek, Tea Gogishvili, Razieh Monjezi, et al.
Science Translational Medicine|July 5, 2019
The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cellsKatrin Mestermann, Theodoros Giavridis, Justus Weber, et al.
Theranostics|February 24, 2022
CD40- and 41BB-specific antibody fusion proteins with PDL1 blockade-restricted agonismJuliane Medler, Kirstin Kucka, Vinicio Melo, et al.
Gene Therapy|April 13, 2021
CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myelomaSabrina Prommersberger, Michael Reiser, Julia Beckmann, et al.
Cancer Immunology Research|October 31, 2014
Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cellsCarolina Berger, Daniel Sommermeyer, Michael Hudecek, et al.
Cancers|November 27, 2024
Cellular Therapies for Multiple Myeloma: Engineering HopeSarah Vera-Cruz, Maria Jornet Culubret, Verena Konetzki, et al.
Journal for Immunotherapy of Cancer|April 19, 2020
<b>Inhibition of TGF-</b>β-<b>receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer</b>Tanja Stüber, Razieh Monjezi, Lars Wallstabe, et al.
Pageof 14

Showing results (51-60 of 139) with videos related to

Sort By:
Pageof 14
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 27, 2013
Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cellsMichael Hudecek, Maria-Teresa Lupo-Stanghellini, Paula L Kosasih, et al.
Journal for Immunotherapy of Cancer|April 29, 2025
Tailoring CAR surface density and dynamics to improve CAR-T cell therapyAna Hinckley-Boned, Carmen Barbero-Jiménez, Maria Tristán-Manzano, et al.
Cancer Immunology Research|September 13, 2014
The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activityMichael Hudecek, Daniel Sommermeyer, Paula L Kosasih, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|January 20, 2017
Minicircle-Based Engineering of Chimeric Antigen Receptor (CAR) T CellsMichael Hudecek, Tea Gogishvili, Razieh Monjezi, et al.
Science Translational Medicine|July 5, 2019
The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cellsKatrin Mestermann, Theodoros Giavridis, Justus Weber, et al.
Theranostics|February 24, 2022
CD40- and 41BB-specific antibody fusion proteins with PDL1 blockade-restricted agonismJuliane Medler, Kirstin Kucka, Vinicio Melo, et al.
Gene Therapy|April 13, 2021
CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myelomaSabrina Prommersberger, Michael Reiser, Julia Beckmann, et al.
Cancer Immunology Research|October 31, 2014
Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cellsCarolina Berger, Daniel Sommermeyer, Michael Hudecek, et al.
Cancers|November 27, 2024
Cellular Therapies for Multiple Myeloma: Engineering HopeSarah Vera-Cruz, Maria Jornet Culubret, Verena Konetzki, et al.
Journal for Immunotherapy of Cancer|April 19, 2020
<b>Inhibition of TGF-</b>β-<b>receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer</b>Tanja Stüber, Razieh Monjezi, Lars Wallstabe, et al.
Pageof 14